Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.96 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 2/20 | 0.38 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4A | O75164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26431397 | 1.00 | SIGMAR1 (0.96) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| Hydrochloric Acid SCHEMBL9718246 | 0.98 | SIGMAR1 (0.92) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| SCHEMBL8092983 | 0.98 | SIGMAR1 (1.00) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| SCHEMBL6969290 | 0.98 | SIGMAR1 (0.91) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| SCHEMBL27368119 | 0.93 | SIGMAR1 (0.83) | SIGMAR1CYP1A2MAPTEPHX1 | |
| SCHEMBL1859093 | 0.93 | SIGMAR1 (0.83) | SIGMAR1CYP1A2MAPTEPHX1 | |
| SCHEMBL19631563 | 0.91 | SIGMAR1 (0.88) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| SCHEMBL22697176 | 0.91 | SIGMAR1 (0.88) | SIGMAR1CYP1A2MAPTEPHX1TNKS2 | |
| SCHEMBL1858791 | 0.91 | SIGMAR1 (0.79) | SIGMAR1CYP1A2MAPTEPHX1 | |
| SCHEMBL6962219 | 0.88 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206325-A1 | NOVEL NUCLEIC ACID MOLECULE INHIBITING EXPRESSION OF TARGET GENE | BONAC CORPORATION (JP) | 2023-07-05 | — | — | EP | disclosed |
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | EMORY UNIVERSITY (US) | 2012-01-26 | — | — | US | disclosed |
| EP-0870765-B1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARM CO LTD (JP) | 2003-11-19 | — | — | EP | disclosed |
| US-5981557-A | HAVING IMPROVING EFFECTS ON THE DYSMOTILITY IN THE GASTROINTESTINAL TRACT | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| EP-0870765-A1 | AMINOTHIAZOLE DERIVATIVES, DRUG CONTAINING THE SAME AND INTERMEDIATE IN THE PRODUCTION OF THE COMPOUNDS | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5153327-A | 7-Oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E. R. SQUIBB & SONS, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0374952-A2 | 7-Oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022070-A1 | Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use | HSP90AB1, HSP90AA1, HSP90AB2P | SIGMAR1 3928/4885CYP1A2 3967/4885MAPT 357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.